PT-141 max dosage: the approved ceiling is 1.75 mg subcutaneously, once per 24 hours. Learn what higher doses do and why the label limit exists.
PT-141 (bremelanotide) has one FDA-approved maximum dose: 1.75 mg injected subcutaneously, no more than once every 24 hours and no more than eight doses per month. That ceiling comes from the Vyleesi prescribing information, which covers premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). No higher dose has been approved for any use in the United States, and no clinical trial has established a safe upper limit above the label.
What PT-141 Is and Why the Dose Is Capped
PT-141 is a synthetic peptide that activates melanocortin receptors, mainly MC4R, in the central nervous system. It works on desire pathways rather than on blood flow, which is why it is not a substitute for erectile dysfunction drugs.
The FDA approved injectable bremelanotide in 2019 under the brand name Vyleesi. It is prescription-only, and it is not approved for men, for bodybuilding, or for general recreational use.
That context matters when reading online dose charts. Anyone comparing peptide pt 141 dosage tables should know that most published numbers come from early research protocols, not from approved prescribing information.
The Approved Maximum: 1.75 mg Per Injection
The label is unusually specific, and the limits are cumulative rather than per-session.
- Maximum single dose: 1.75 mg
- Route: subcutaneous injection into the abdomen or thigh
- Timing: at least 45 minutes before anticipated sexual activity
- Minimum interval: 24 hours between doses
- Monthly cap: 8 doses
The pt-141 injection dosage on the label is a ceiling, not a starting suggestion. The dose does not scale with body weight, and it does not increase based on how quickly someone wants results.
Two injections in one day is not a stronger version of the approved treatment. It is an unstudied exposure that adds side effects without adding benefit.
There is no approved PT-141 dose above 1.75 mg, and no study has established a safe maximum beyond the label.
What Happens Above 1.75 mg
Higher doses of bremelanotide were studied during drug development and consistently produced more adverse events. Nausea, flushing, headache, and vomiting were the most common, and they scaled with dose rather than staying flat.
Blood pressure is the larger concern. PT-141 causes a transient rise in blood pressure and a small drop in heart rate after each dose, which is why the label carries warnings for people with cardiovascular disease or uncontrolled hypertension.
Hyperpigmentation with repeated dosing
Focal hyperpigmentation, or darkening of the face, gums, or breast skin, has been reported with repeated use. It appears more often in people who dose frequently, which is one reason the eight-dose monthly cap exists.
PT-141 is not approved for men, and no male-specific maximum dose exists in any regulatory labeling.
Why stacking doses doesn't help
PT-141 is eliminated from the body on a predictable timeline, so a second dose does not build on the first in a useful way. It simply extends the period during which side effects can occur.
Route Matters: Injection vs. Nasal Spray
Only the subcutaneous injection is approved. Compounded nasal sprays are widely sold, but absorption through the nose is variable, and a pt 141 nasal spray dosage is not interchangeable with the injected product.
| Route | Regulatory status | Approved or typical dose | Key considerations |
|---|---|---|---|
| Subcutaneous injection (Vyleesi) | FDA-approved for premenopausal women with HSDD | 1.75 mg, once per 24 hours, max 8 per month | Predictable absorption; transient blood pressure rise |
| Nasal spray (compounded) | Not FDA-approved | Varies by pharmacy; no standard exists | Variable absorption; potency not guaranteed |
| Oral | Not available | Not established | Poor bioavailability for a peptide |
A pt-141 dosage subcutaneous protocol and a nasal protocol cannot be compared milligram for milligram. The two routes deliver different amounts of drug to the bloodstream, sometimes on very different timelines.
Who Should Not Use PT-141 at Any Dose
Certain conditions rule the medication out entirely, regardless of how small the dose is.
- Uncontrolled high blood pressure
- Known cardiovascular disease
- Current use of oral naltrexone
- Pregnancy or breastfeeding
PT-141 has not been studied in postmenopausal women, and there is no approved pt 141 dosage for men. Off-label use in those groups is a clinical judgment call, not a self-directed one.
Bodybuilding communities sometimes discuss the peptide for libido or performance goals. There is no clinical evidence supporting that use, and the cardiovascular warnings apply no matter why the drug is taken.
If 1.75 mg Isn't Working, Talk to Your Prescriber
If the approved dose isn't producing the result you expect, the answer is not a larger injection. Underlying factors such as medication side effects, hormonal changes, relationship stress, and mood disorders often influence low desire more than dose does.
Prescribers can review timing, injection technique, and whether a different treatment fits better. They can also check blood pressure before and after starting the medication, since PT-141 raises it temporarily.
Buying unregulated peptides online adds a second layer of risk. A vial may contain a different amount of drug than the label states, which makes any dose calculation meaningless.
The safest approach is to use FDA-approved product from a licensed pharmacy and to never adjust your own dose without medical guidance.
Frequently Asked Questions
What is the maximum dose of PT-141?
The FDA-approved maximum is 1.75 mg given as a single subcutaneous injection. It should not be repeated within 24 hours, and no more than eight doses should be used in a month. Higher doses have not been approved and are not supported by clinical evidence.
What happens if you take too much PT-141?
Exceeding the approved dose increases the risk of nausea, vomiting, flushing, headache, and injection-site reactions. It can also cause a temporary rise in blood pressure and a drop in heart rate, and repeated high-frequency use has been linked to focal hyperpigmentation. Seek medical care for severe symptoms such as chest pain or a sustained blood pressure increase.
Is PT-141 approved for men or for bodybuilding?
No. Vyleesi is approved only for premenopausal women with acquired, generalized hypoactive sexual desire disorder. There is no approved male dose and no clinical evidence supporting bodybuilding use, and off-label use carries the same cardiovascular warnings.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.